What is the main accounting issue discussed regarding Medicare Part D?

The main issue is how UnitedHealth Group (UNH) accounts for revenue and pharmacy benefit costs during interim reporting periods for its Medicare Part D contract. While annual reporting aligns under GAAP and management's preferred "Management Reporting," the latter allows for deferring certain costs in earlier quarters to match them with revenue over the full contract year, reflecting the company's view of interim periods as integral parts of an annual contract.

Will the accounting treatment for Medicare Part D affect UNH's first-quarter 2006 results?

No, the company explicitly states that the outcome of SEC discussions regarding Part D interim period reporting has no impact on its outlook for first-quarter results. UNH expects to announce its first-quarter results on April 18, 2006, and will present them on both a GAAP basis and a "Management Reporting" basis.

Why is UNH reviewing its stock option grant practices?

The review was initiated due to increased focus from the Securities and Exchange Commission and others on stock option grant practices across publicly traded companies. The CEO recommended, and the Board of Directors accepted, the formation of a committee of independent directors to conduct this review with outside legal counsel.

Are there any legal proceedings related to the stock option review?

Yes, the filing mentions that on March 29, 2006, a derivative action lawsuit related to the issues being reviewed by the stock option committee was filed in the U.S. District Court for the District of Minnesota. The defendants include all directors except Donna Shalala, with the Company named as a nominal defendant.

UNH 8-K: Regulation FD

Summary

UnitedHealth Group (UNH) filed an 8-K on April 7, 2006, primarily addressing two key areas: accounting for its Medicare Part D contract and a review of its stock option practices. Regarding Medicare Part D, the company clarified its accounting treatment for interim periods, differentiating between Generally Accepted Accounting Principles (GAAP) and its internal "Management Reporting." While both methods align for annual reporting, Management Reporting allows for deferral of certain pharmacy benefit costs in earlier interim periods to better match them with revenue recognition over the annual contract. This approach has been discussed with the SEC and is deemed appropriate by the company as it views each interim period as part of an integral annual contract, aligning with expected full-year benefit utilization. Additionally, the 8-K disclosed the formation of a committee of independent directors to review the company's historical and current stock option grant practices, prompted by broader industry scrutiny and SEC focus. This review, conducted with independent legal counsel, was initiated by the CEO. The filing also notes a derivative lawsuit related to stock option issues filed against the directors. Importantly, the company stated that the SEC discussions on Part D interim reporting have no impact on its outlook for first-quarter results, which are scheduled to be announced on April 18, 2006.

Key Highlights

1UNH clarified its accounting for Medicare Part D interim reporting with the SEC, distinguishing between GAAP and "Management Reporting" methods.
2Under "Management Reporting," UNH may defer a portion of pharmacy benefit costs in earlier interim periods to align with revenue recognition over the annual CMS contract.
3Both GAAP and "Management Reporting" methods yield the same results for annual financial statements.
4The company views its interim Medicare Part D reporting as integral to the full annual contract period.
5A committee of independent directors has been formed to review UNH's current and historical stock option grant practices.
6Independent legal counsel has been engaged to assist with the stock option review.
7The outcome of the SEC discussions on Part D interim reporting does not affect UNH's 2006 first-quarter earnings outlook.

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Apr 7, 2006)

Summary

Key Highlights

Frequently Asked Questions